10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
Key Takeaways
- Fatty acid synthesis occurs in the cytosol from acetyl-CoA via the citrate shuttle, governed by the rate-limiting enzyme Acetyl-CoA Carboxylase (ACC), which requires Biotin (B7) and is activated by citrate/insulin.
- Fatty acid beta-oxidation occurs in the mitochondrial matrix via the carnitine shuttle (CPT-I rate-limiting, inhibited by malonyl-CoA); MCAD deficiency causes hypoketotic hypoglycemia during fasting.
- Ketogenesis in liver mitochondria produces acetoacetate, beta-hydroxybutyrate, and acetone under high acetyl-CoA conditions, serving as alternative fuel for extrahepatic tissues during starvation or DKA.
- Lipoproteins transport hydrophobic lipids: Chylomicrons (ApoB-48, dietary lipids), VLDL (ApoB-100, endogenous liver triglycerides), LDL (ApoB-100, cholesterol to tissues via LDLR), and HDL (ApoA-I, reverse cholesterol transport via LCAT).
10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
Lipids represent the body's major energy reserve and essential structural components of biological membranes. Lipid metabolism involves coordinated synthesis (lipogenesis), degradation ($\beta$-oxidation), ketone body formation (ketogenesis), and systemic transport via specialized lipoprotein particles. Understanding these biochemical processes and their pathology is crucial for the NPLEX Part I exam.
Fatty Acid Synthesis (De Novo Lipogenesis)
Occurring primarily in the cytosol of liver and lactating mammary gland cells during the fed state, de novo lipogenesis converts excess dietary carbohydrate into long-chain fatty acids (primarily Palmitate, 16C).
The Citrate Shuttle
Acetyl-CoA produced in the mitochondrial matrix cannot cross the inner mitochondrial membrane directly. Under high energy charges, accumulated citrate is exported to the cytosol via the citrate shuttle:
- Cytosolic ATP-Citrate Lyase cleaves Citrate $\rightarrow$ Acetyl-CoA + Oxaloacetate.
Rate-Limiting Step & Regulation
- Rate-Limiting Enzyme: Acetyl-CoA Carboxylase (ACC).
- Reaction: Acetyl-CoA (2C) $+ \text{HCO}_3^- + \text{ATP} \longrightarrow$ Malonyl-CoA (3C).
- Cofactor Required: Biotin (Vitamin B7).
- Regulation:
- Activated by: Insulin (dephosphorylation) and Citrate (allosteric polymerized active state).
- Inhibited by: Glucagon / Epinephrine (PKA phosphorylation) and Palmitoyl-CoA (end-product feedback inhibition).
Fatty Acid Synthase Complex
A multifunctional homodimer utilizing NADPH (derived from the HMP shunt and Malic Enzyme) to sequentially elongate malonyl-CoA units, producing Palmitate (16:0).
Fatty Acid Oxidation ($\beta$-Oxidation)
During fasting or exercise, free fatty acids released from adipose tissue via hormone-sensitive lipase are oxidized in the mitochondrial matrix to produce energy.
The Carnitine Shuttle
Long-chain fatty acids (LCFAs) in the cytosol are activated to Fatty Acyl-CoA by Acyl-CoA synthetase. Entry into the mitochondrial matrix requires the Carnitine Shuttle:
- Carnitine Palmitoyltransferase-I (CPT-I / CAT-I): Located on the outer mitochondrial membrane. The rate-limiting enzyme of $\beta$-oxidation; converts Fatty Acyl-CoA + Carnitine $\rightarrow$ Fatty Acylcarnitine.
- Inhibition: Strongly inhibited by Malonyl-CoA (prevents simultaneous fatty acid synthesis and degradation).
- Carnitine-Acylcarnitine Translocase: Translocates Fatty Acylcarnitine across inner membrane.
- Carnitine Palmitoyltransferase-II (CPT-II): On inner membrane; regenerates Fatty Acyl-CoA and free carnitine in matrix.
Cytosol Outer Membrane Inner Membrane Matrix
Fatty Acyl-CoA + Carnitine ──[ CPT-I ]──► Fatty Acylcarnitine ──[ Translocase ]──► Fatty Acyl-CoA + Carnitine
▲ │
Inhibited by β-Oxidation Cycle
Malonyl-CoA │
▼
Acetyl-CoA + NADH + FADH2
The $\beta$-Oxidation Cycle
Each cycle shortens the acyl chain by 2 carbons, producing:
- 1 Acetyl-CoA (enters TCA cycle or ketogenesis)
- 1 NADH (enters ETC Complex I)
- 1 $\text{FADH}_2$ (enters ETC Complex II / ETF)
Metabolic Disorders of $\beta$-Oxidation
- Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: Autosomal recessive defect in initial step of $\beta$-oxidation for 6-to-12 carbon fatty acids.
- Presentation: Triggered by prolonged fasting or illness. Features hypoketotic hypoglycemia, lethargy, seizures, hepatomegaly, and sudden death. Laboratory shows elevated dicarboxylic acids in urine and low plasma ketones.
- Systemic Primary Carnitine Deficiency: Defective carnitine transporter preventing LCFA entry into mitochondria. Hypoketotic hypoglycemia, hypotonia, and dilated cardiomyopathy.
Ketogenesis & Ketone Body Utilization
During prolonged starvation, low carbohydrate intake, or Diabetic Ketoacidosis (DKA), oxaloacetate in hepatocytes is consumed for gluconeogenesis. Accumulated Acetyl-CoA from massive $\beta$-oxidation exceeds TCA cycle capacity and is shunted into Ketogenesis within liver mitochondria.
Pathway & Key Enzymes
- Rate-Limiting Enzyme: HMG-CoA Synthase (mitochondrial).
- Ketone Body Products:
- Acetoacetate: Primary ketone body.
- $\beta$-Hydroxybutyrate: Most abundant circulating ketone body (reduced form of acetoacetate; measured in blood).
- Acetone: Volatile breakdown product excreted via lungs, responsible for characteristic fruity breath odor.
Extrahepatic Utilization
Ketone bodies exit hepatocytes into blood and are converted back to Acetyl-CoA in peripheral tissues (brain, cardiac muscle, skeletal muscle) for ATP production. The liver cannot utilize ketone bodies because it lacks the enzyme Thiophorase (Succinyl-CoA:3-ketoacid CoA transferase / SCOT).
Lipoprotein Transport & Metabolism
Lipoproteins are spherical complexes transporting hydrophobic lipids (triglycerides, cholesterol esters) within a hydrophilic shell of phospholipids, free cholesterol, and apolipoproteins.
Summary of Lipoprotein Classes
| Lipoprotein | Primary Lipid Content | Major Apolipoprotein(s) | Primary Physiological Function |
|---|---|---|---|
| Chylomicron | Dietary Triglycerides (85-90%) | ApoB-48, ApoC-II, ApoE | Delivers dietary lipids from intestine to peripheral tissues (muscle, adipose). |
| VLDL | Endogenous Hepatic Triglycerides (55-65%) | ApoB-100, ApoC-II, ApoE | Delivers de novo hepatic triglycerides to peripheral tissues. |
| IDL | Triglycerides and Cholesterol | ApoB-100, ApoE | VLDL remnant; converted to LDL by hepatic lipase or taken up by liver. |
| LDL | Cholesterol Esters (50%) | ApoB-100 | Delivers cholesterol to peripheral tissues via LDL-receptor endocytosis. |
| HDL | Protein (50%), Phospholipids | ApoA-I, ApoC-II, ApoE | Executes reverse cholesterol transport (scavenges cholesterol from tissues to liver). |
Key Apolipoproteins & Functions
- ApoB-48: Mediates chylomicron secretion from enterocytes into lymphatics.
- ApoB-100: Mediates VLDL assembly/secretion from hepatocytes; acts as ligand for LDL Receptor.
- ApoC-II: Cofactor that activates Lipoprotein Lipase (LPL) on capillary endothelial surfaces, hydrolyzing triglycerides into free fatty acids and glycerol.
- ApoE: Mediates remnant clearance by binding ApoE receptors on hepatocytes.
- ApoA-I: Activates Lecithin-Cholesterol Acyltransferase (LCAT / PCAT) on HDL, esterifying free cholesterol for reverse transport.
Familial Hyperlipidemias
| Type | Inherited Disorder | Defective Protein / Gene | Pathophysiology & Clinical Manifestations |
|---|---|---|---|
| Type I | Familial Hyperchylomicronemia | Lipoprotein Lipase (LPL) or ApoC-II | Severe elevation of chylomicrons and triglycerides in plasma. Recurrent acute pancreatitis, eruptive xanthomas, hepatosplenomegaly. No increased CAD risk. Creamy supernatant layer in standing plasma. |
| Type IIa | Familial Hypercholesterolemia | LDL Receptor ($LDLR$) or ApoB-100 | Severe elevation of LDL and serum cholesterol. Accelerated premature coronary artery disease (CAD), tendon xanthomas (Achilles tendon), and xanthelasma (palpebral). Heterozygotes cholesterol $\approx 300\text{ mg/dL}$; Homozygotes $\approx 700+\text{ mg/dL}$ (severe MI in childhood). |
| Type III | Familial Dysbetalipoproteinemia | ApoE2 homozygosity | Impaired hepatic clearance of chylomicron remnants and IDL. Elevated chylomicron remnants and VLDL. Premature atherosclerosis, tuberoeruptive xanthomas, and palmar xanthomas (yellow palmar creases). |
A 14-month-old child presents with lethargy and vomiting following an episode of viral gastroenteritis during which she had minimal oral intake. Laboratory findings reveal severe hypoglycemia (32 mg/dL) with absent urinary ketone bodies. Plasma acylcarnitine profiling shows accumulation of medium-chain dicarboxylic acids. Deficiency of which enzyme is the cause of this presentation?
A 34-year-old male with a history of severe hypercholesterolemia presents with firm, non-tender nodules over his Achilles tendons. His father died of a myocardial infarction at age 41. Laboratory analysis shows a plasma total cholesterol level of 380 mg/dL with markedly elevated LDL. Which molecular defect is responsible for this condition?
Hepatic de novo fatty acid synthesis is tightly regulated to prevent futile cycling with beta-oxidation. Which metabolite produced during fatty acid synthesis directly inhibits mitochondrial Carnitine Palmitoyltransferase-I (CPT-I), thereby preventing entry of fatty acids into the matrix for degradation?